Gilead Sciences, Inc. has unveiled impressive results from its Phase 3 PURPOSE 1 trial, highlighting lenacapavir’s potential as a breakthrough in HIV prevention. The data, presented at the 25th International AIDS Conference in Munich and published in The New England Journal of Medicine, demonstrate that the twice-yearly injectable HIV-1 capsid inhibitor achieved zero infections among participants, marking 100% efficacy. Lenacapavir outperformed the once-daily oral PrEP, Truvada, showing superior prevention capabilities. The trial also underscored high adherence rates to lenacapavir, contrasting with lower adherence to daily oral PrEP. Linda-Gail Bekker, Director of the Desmond Tutu HIV Center, praised the results, noting that lenacapavir could significantly enhance PrEP uptake and persistence, potentially reducing HIV rates in cisgender women globally. In response, Gilead is focusing on rapid regulatory approval and access strategies to address HIV in high-incidence, resource-limited regions. The independent Data Monitoring Committee has recommended ending the blinded phase, allowing over 840 participants to switch to lenacapavir. For the LGBTQ+ community, this represents a groundbreaking advancement in HIV prevention, offering a highly effective and discrete option. #Queer Up Health